These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 20636279)

  • 1. An effective HIV vaccine: A combination of humoral and cellular immunity?
    Benmira S; Bhattacharya V; Schmid ML
    Curr HIV Res; 2010 Sep; 8(6):441-9. PubMed ID: 20636279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of Vaccine-Induced CD4 T Cell Functional Profiles by Changes in Components of HIV Vaccine Regimens in Humans.
    Pissani F; Schulte B; Eller MA; Schultz BT; Ratto-Kim S; Marovich M; Thongcharoen P; Sriplienchan S; Rerks-Ngarm S; Pitisuttithum P; Esser S; Alter G; Robb ML; Kim JH; Michael NL; Streeck H
    J Virol; 2018 Dec; 92(23):. PubMed ID: 30209165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prime/boost immunization with HIV-1 MPER-V3 fusion construct enhances humoral and cellular immune responses.
    Bolhassani A; Kardani K; Vahabpour R; Habibzadeh N; Aghasadeghi MR; Sadat SM; Agi E
    Immunol Lett; 2015 Dec; 168(2):366-73. PubMed ID: 26518142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospects for a globally effective HIV-1 vaccine.
    Excler JL; Robb ML; Kim JH
    Vaccine; 2015 Nov; 33 Suppl 4():D4-12. PubMed ID: 26100921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.
    Nyombayire J; Anzala O; Gazzard B; Karita E; Bergin P; Hayes P; Kopycinski J; Omosa-Manyonyi G; Jackson A; Bizimana J; Farah B; Sayeed E; Parks CL; Inoue M; Hironaka T; Hara H; Shu T; Matano T; Dally L; Barin B; Park H; Gilmour J; Lombardo A; Excler JL; Fast P; Laufer DS; Cox JH;
    J Infect Dis; 2017 Jan; 215(1):95-104. PubMed ID: 28077588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
    Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine.
    Shen X; Basu R; Sawant S; Beaumont D; Kwa SF; LaBranche C; Seaton KE; Yates NL; Montefiori DC; Ferrari G; Wyatt LS; Moss B; Alam SM; Haynes BF; Tomaras GD; Robinson HL
    J Virol; 2017 Dec; 91(24):. PubMed ID: 29021394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV vaccines: progress to date.
    Munier CM; Andersen CR; Kelleher AD
    Drugs; 2011 Mar; 71(4):387-414. PubMed ID: 21395355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvants: tailoring humoral immune responses.
    McElrath MJ
    Curr Opin HIV AIDS; 2017 May; 12(3):278-284. PubMed ID: 28257301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges in the development of an HIV-1 vaccine.
    Barouch DH
    Nature; 2008 Oct; 455(7213):613-9. PubMed ID: 18833271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospects for a Globally Effective HIV-1 Vaccine.
    Excler JL; Robb ML; Kim JH
    Am J Prev Med; 2015 Dec; 49(6 Suppl 4):S307-18. PubMed ID: 26590431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current views on the potential for development of a HIV vaccine.
    Cohen KW; Frahm N
    Expert Opin Biol Ther; 2017 Mar; 17(3):295-303. PubMed ID: 28095712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV gp120 vaccine - VaxGen: AIDSVAX, AIDSVAX B/B, AIDSVAX B/E, HIV gp120 vaccine - Genentech, HIV gp120 vaccine AIDSVAX - VaxGen, HIV vaccine AIDSVAX - VaxGen.
    Adis International Ltd
    Drugs R D; 2003; 4(4):249-53. PubMed ID: 12848591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterologous HIV-based lentiviral/adenoviral vectors immunizations result in enhanced HIV-specific immunity.
    Asefa B; Korokhov N; Lemiale F
    Vaccine; 2010 Apr; 28(20):3617-24. PubMed ID: 20051277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV vaccines in infants and children.
    Lambert JS
    Paediatr Drugs; 2005; 7(5):267-76. PubMed ID: 16220994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralizing antibody responses to HIV: role in protective immunity and challenges for vaccine design.
    Srivastava IK; Ulmer JB; Barnett SW
    Expert Rev Vaccines; 2004 Aug; 3(4 Suppl):S33-52. PubMed ID: 15285704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [HIV vaccines].
    Pialoux G; Slama L
    Presse Med; 2005 Nov; 34(20 Pt 2):1592-6. PubMed ID: 16314820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Architectural insight into inovirus-associated vectors (IAVs) and development of IAV-based vaccines inducing humoral and cellular responses: implications in HIV-1 vaccines.
    Hassapis KA; Stylianou DC; Kostrikis LG
    Viruses; 2014 Dec; 6(12):5047-76. PubMed ID: 25525909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress in HIV vaccine development.
    Hsu DC; O'Connell RJ
    Hum Vaccin Immunother; 2017 May; 13(5):1018-1030. PubMed ID: 28281871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and efficacy of DNA/MVA HIV vaccines in rhesus macaque models.
    Chea LS; Amara RR
    Expert Rev Vaccines; 2017 Oct; 16(10):973-985. PubMed ID: 28838267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.